12:00 AM
Jul 17, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

HE2000: Phase I/II

HEPH said that HE2000 significantly increased levels of CD4 and CD8 T cells, dendritic cells, natural killer and lymphokine-activated killer cells versus baseline in its 37-patient South African Phase I/II study,...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >